In a report published Thursday, Goldman Sachs analyst Isaac Ro reiterated a Neutral rating on Illumina ILMN, and raised the price target from $59.00 to $64.00.
In the report, Goldman Sachs noted, “We believe BaseSpace is still in its infancy and unlikely to be a material driver of revenue in the near-term. However, we believe the infrastructure and long-term competitive advantages are underappreciated for the following reasons: 1) BaseSpace gives ILMN optimal visibility on customer usage trends which help forecasting and customer targeting. 2) It provides insight on potential quality issues to ensure superior service. 3) Long-term, it will help ILMN establish its platform and accumulated database of genomes as the standard in research and eventually clinical labs.”
Illumina closed on Wednesday at $74.69.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in